Azenta's 15min chart exhibits bearish Marubozu with Bollinger Bands expanding downward.

The 15-minute chart for Azenta has recently displayed Bollinger Bands expanding downward and a bearish Marubozu candlestick pattern on September 12th at 11:15. This suggests that the market trend is being driven by selling pressure, with sellers exerting control over the market. Consequently, it is likely that bearish momentum will persist in the short term.

Tempus AI, Inc. (TEM) reported robust second-quarter results, showcasing significant growth and innovation in the precision medicine and AI-driven healthcare sectors. The company's revenue grew by 89.6% year-over-year, with full-year revenues expected to reach approximately $1.26 billion, up from the earlier projection of $1.25 billion. This represents nearly an 82% annual growth rate TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1].

The quarterly gross profit surged by 158.3% from the year-ago quarter, while adjusted gross margin expanded by 1649 basis points despite a 32.2% rise in the cost of revenues. Tempus AI's adjusted EBITDA improved sequentially, moving from a negative $16 million in the previous quarter to a negative $5.6 million in the second quarter. The company expects a positive adjusted EBITDA of $5 million in 2025 TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1].

Innovation was a key driver of Tempus AI's performance. The company expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer and introduced xM, a liquid biopsy assay for treatment response monitoring (TRM) TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1].

Tempus AI's stock has outperformed industry peers and benchmarks, with year-to-date (YTD) performance of 137.6%, compared to the Medical Info Systems industry's 24.7% and the S&P 500's 10.8% TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1]. The company's acquisitions, including Paige, Deep 6 AI, and Ambry Genetics, have bolstered its leadership position and expanded its reach TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1].

However, Tempus AI faces challenges related to reimbursement for certain product segments, which may limit revenue growth and margin expansion potential. The company's forward five-year price-to-sales (P/S) ratio of 9.41X is higher than the industry average of 5.84X, indicating an expensive valuation TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?^[1].